Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

What 10 Analyst Ratings Have To Say About Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

Benzinga

FDA advisory panel to discuss Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

Moderna Says Infant Covid Vaccine Succeeded in Trial

US biotech firm Moderna on Wednesday said it was pursuing regulatory approval for its Covid vaccine in children under six years old after the two-shot regimen was found to be safe and produced a strong immune response. Specifically, two doses of 25 micrograms given to babies, toddlers and preschoolers generated…

Asharq Al-Awsat

Two-month-old baby's death in Newcastle confirmed to be from COVID-19

The NSW coroner has confirmed a two-month-old baby died of COVID-19 in December. The child is believed to be Australia's youngest COVID victim.

ABC News

EXPLAINER: What to know about COVID vaccines for little kids

Moderna says it will ask regulators to authorize its COVID-19 vaccine for children under 6 but several hurdles need to be cleared before the shots could become available

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Australia secures Moderna vaccine facility

Hundreds of millions of mRNA vaccines will be made in Australia as part of a multi-billion dollar agreement with pharmaceutical giant Moderna.

AAP

Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6

Moderna Inc (NASDAQ:MRNA) has announced interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273) in children six months to under six years. The interim analysis showed that two 25 μg doses of mRNA-1273 in participants 6 months to under six years met the primary endpoint with robust neutralizing antibody…

Benzinga

Moderna to seek emergency authorization for COVID-19 vaccine use for kids under 6

Kids, prep those arms.

Tribune News Service

Moderna will produce its mRNA vaccines in Australia from 2024, with final deal signed off

The plant will have the capacity to produce up to 100 million vaccine doses each year, for COVID-19 and for other diseases like the seasonal flu.

ABC News

Moderna says vaccine for kids under 6 generates strong immune response

"This interim analysis showed a robust neutralizing antibody response in both age groups."

Axios

Moderna says its low-dose COVID shots work for kids under 6

Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers

The Independent UK

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Moderna Shares Are Trading Higher Today

Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday after the company announced two new vaccine candidate developments.

Benzinga

Moderna Bolsters Its Pipeline With Two New mRNA-Based Vaccine Programs

Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…

The Independent UK

No funds to buy fourth Covid vaccine dose for all Americans, White House warns

Funding for coronavirus aid stalled in Congress leaving vaccine and therapeutics purchases lacking

Tribune News Service

COVID’s ‘silver lining’: Research breakthroughs for chronic disease, cancer and the common flu

The billions of dollars invested in COVID vaccines and COVID-19 research so far are expected to yield medical and scientific dividends for decades, helping doctors battle influenza, cancer, cystic fibrosis and far more diseases.

Get all your
news in one place.

100’s of premium titles.
One news app.

Los Angeles Times

California could see coronavirus uptick this spring because of omicron subvariant BA.2

LOS ANGELES — Coronavirus cases are on the upswing worldwide, prompting some officials to warn that California could see increases this spring because of the omicron subvariant BA.2 even though cases so far have been modest.

Benzinga

Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market

After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock.

Businessweek

The Future of Boosters Is Somewhere Between Unnecessary and Urgent

Until there’s a universal coronavirus vaccine, the future of additional shots is a murky work in progress—but more rounds seem increasingly likely.

Benzinga

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose

Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a

Asharq Al-Awsat

Moderna Seeks US Approval of Second Covid Booster

Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company's Covid-19 vaccine for all adults. The request to the US Food and Drug Administration (FDA) would "allow for a fourth dose of our #COVID19 vaccine in adults 18…

Evening Standard

Moderna seeks emergency authorisation for second Covid booster in US

Moderna is seeking emergency use authorisation from US regulators for its second dose of a Covid-19 vaccine booster shot.

1 … 28 29 30 31

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

336 stories

Centers for Disease Control and Prevention

National Institutes of Health

78 stories

European Medicines Agency

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.